Abstract:Background Hepatic, hematologic and other adverse events (AE) during treatment in RA patients are unavoidable. And monitoring AE in long-term treatment is quite necessary as a part of chronic disease management. SSDM is a smart mobile tool to help patients upload their therapeutic regimens, lab test records and report AEs. Our previous study showed that patients in China can master the application of SSDM after training. Objectives To determine and compare the incidence of adverse events during treatment of RA with different therapeutic regimens, focusing on mono and combination therapy. Methods The SSDM includes interfaces of both physicians’ and patients’ application. Patients were educated to enter the data of lab test records and treatment regiments once a month, all data can be synchronised automatically to the authorised physicians’ mobile tool, which formed a large patient reported database. The rheumatologists can also adjust treatment regiments base on patients’ profile. Results From Aug 2014 to Jan 2018, a total of 7048 RA patients from 480 centres in China were entered in the cohort study. These patients contributed more than 12 600 patient-years (PY) of total followup. The mean age was 48.98±16.08 (18 to 99) years and the median disease duration was 23.27 months. The treatment regimens include mono or combination of leflunomide(LEF), MTX, hydroxycholoqine (HCQ), sulfasalazine(SSZ), glucocorticoid(GC), biologic DMARD, Tripterygium wilfordii, meloxicam, celecoxib, iguratimod, etc. In this database the five most common treatment regimens is LEF monotherapy (3801 PY), MTX monotherapy (1321 PY), LEF +MTX (1086 PY), HCQ monotherapy (715 PY), LEF +HCQ (576 PY). The incidence rate of hepatic events was lower for LEF monotherapy (35 events/1000 PY) than MTX (52 events/1000 PY) and LEF +MTX combination therapy (115 events/1000 PY) (p<0.01). The incidence rate of leukopenia was lower for LEF monotherapy (42 events/1000 PY) and MTX monotherapy (39 events/1000 PY) than LEF +MTX combination therapy (84 events/1000 PY) (p<0.01). Conclusions The findings show that mono or combination of csDMARDs are the most commonly used drugs in Chinese RA patients. And AEs may be well described in this patient report database because of the large sample sizes and empowering patient themselves. RA patients can get better safety in the long-term treatment via SSDM. Disclosure of Interest None declared

From common to unreported: a real-world study of adverse events to duloxetine in the treatment of osteoarthritis

Clinical Therapeutic Recommendation on Duloxtine in Treatment of Major Depressive Disorder and Generalized Anxiety Disorder

A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine

Perioperative Duloxetine in Total Joint Arthroplasty: An Umbrella Review

Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis

The analgesic effect and safety of duloxetine in total knee arthroplasty: A systematic review

Antihypertensive drug-associated adverse events in osteoarthritis: a study of a large real-world sample based on the FAERS database

Duloxetine combined with intra-articular injection versus intra-articular injection alone for pain relief in knee osteoarthritis: a study protocol for a randomised controlled trial

Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective

Duloxetine reduces opioid consumption and pain after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials

Efficacy and Safety of Duloxetine in Patients with Chronic Low Back Pain Who Used Versus Did Not Use Concomitant Nonsteroidal Anti-Inflammatory Drugs or Acetaminophen: A Post Hoc Pooled Analysis of 2 Randomized, Placebo-Controlled Trials.

A real-world disproportionality analysis of the FDA adverse event reporting system events for ibuprofen

Effect of Duloxetine on Opioid Use and Pain after Total Knee Arthroplasty: A Triple-Blinded Randomized Controlled Trial

The Effectiveness and Safety Analysis of Duloxetine in Treating Comorbid Depression in Parkinson's Disease: A Retrospective Study

Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database

Risk Factors of Adverse Drug Reaction from Non-Steroidal Anti-Inflammatory Drugs in Shanghai Patients with Arthropathy

Duloxetine and Subacute Pain after Knee Arthroplasty when Added to A Multimodal Analgesic Regimen A Randomized, Placebo-Controlled, Triple-Blinded Trial

Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis

Adverse Effects of Opioid Analgesics in Osteoarthritis Treatment: A Global Meta-Analysis, 2000-2022.

Does Screening for Depressive Symptoms Help Optimize Duloxetine Use in Knee Osteoarthritis Patients With Moderate Pain? A Cost‐Effectiveness Analysis

AB0501 Adverse Events with Treatment Regimens of Rheumatoid Arthritis (RA) Reported by Patients Applying Smart System of Disease Management (SSDM) Mobiles Tools: a Cohort Study of Ra Patients in China